drugset / Trial / NCT04784247
Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
Phase 2
Active not recruiting
52 enrolled
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC · collabParker Institute for Cancer Immunotherapy · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether combining the study drugs, lenvatinib and pembrolizumab, is a safe and effective treatment for metastatic soft tissue sarcomas that cannot be removed with surgery.
Timeline
- Start
- 2021-03-18
- Primary completion
- 2027-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 20 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |